Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322443 | 1.00 | CCR1 (0.32) | CCR1CHRM2CCR5PTGS2ALDH1A1 | |
| SCHEMBL1323948 | 0.82 | CCR1 (0.44) | CCR1CHRM2CCR5 | |
| SCHEMBL1323945 | 0.82 | CCR1 (0.44) | CCR1CHRM2CCR5 | |
| SCHEMBL654226 | 0.79 | CCR1 (0.54) | CCR1CHRM2CCR5PTGS2 | |
| SCHEMBL654225 | 0.79 | CCR1 (0.54) | CCR1CHRM2CCR5PTGS2 | |
| SCHEMBL1323955 | 0.75 | CCR1 (0.45) | CCR1CHRM2CCR5 | |
| SCHEMBL1323957 | 0.75 | CCR1 (0.45) | CCR1CHRM2CCR5 | |
| SCHEMBL7733509 | 0.74 | CCR1 (0.42) | CCR1CHRM2CCR5 | |
| SCHEMBL7733512 | 0.74 | CCR1 (0.42) | CCR1CHRM2CCR5 | |
| SCHEMBL5485987 | 0.72 | CCR1 (0.44) | CCR1CHRM2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | CCR1 10/4885CHRM2 1772/4885CCR5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.